| Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European ... - PR Newswire (press release) |
|
|
PR Newswire (press release) Zerenex (ferric citrate), a ferric iron-based phosphate binder, is currently in Phase 3 clinical development in the United States for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis |